Stocktoria
Aclarion, Inc. ACON
Aclarion, Inc. (ACON) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $75,730 at a -9551.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.845 |
| Retained earnings / assets | -4.278 |
| EBIT / assets | -0.516 |
| Equity / liabilities | 15.329 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ACON | Aclarion, Inc. | 4/9 | 4.23 | — | — |
| SERA | SERA PROGNOSTICS, INC. | 2/9 | -8.32 | — | — |
| YDES | YD Bio Ltd | 1/9 | -1.35 | — | — |
| BGLC | BioNexus Gene Lab Corp | 4/9 | 13.26 | — | — |
| CFOR | CapForce Inc. | 2/9 | -14.09 | 1 | — |
| XGN | EXAGEN INC. | 3/9 | -14.91 | — | +19.7% |
| PSNL | Personalis, Inc. | 3/9 | 0.31 | — | -17.7% |
About Aclarion, Inc.
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
FAQ
Is ACON financially healthy?
Aclarion, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ACON pay a dividend?
No, Aclarion, Inc. does not currently pay a dividend.
How profitable is ACON?
In FY2025, Aclarion, Inc. had a net margin of -9551.9% and a return on equity of -56.4%.
What is the analyst price target for ACON?
The average Wall-Street price target for Aclarion, Inc. is $7.50, about 223.3% above the recent price, from 1 analysts.
Is ACON a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Aclarion, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.